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Summary
OBJECTIVES: The aims of this study were to (a) identify
and assess the quality of reporting of published cost-effec-
tiveness studies of bariatric surgery, (b) assess their trans-
ferability to Switzerland, and (c) adapt transferable cost-
effectiveness results to Switzerland.
METHODS: A systematic literature search was performed
in Medline, Embase and other databases. Two reviewers
independently undertook screening, extraction, assess-
ment of reporting quality utilising the Consolidated Health
Economic Evaluation Reporting Standards, transferability,
adaptation of cost data and recalculation of cost-effective-
ness results. Cost data were adapted in three steps: cor-
rection for different levels of resource utilisation, for differ-
ent prices of healthcare services and for change in costs
over time.
RESULTS: Fifteen studies fulfilled criteria for adaptation
of cost data to Switzerland. Four out of fifteen adapted
studies with a long time-horizon for patients with a body
mass index (BMI) >35kg/m2 indicated bariatric surgery to
be a cost-saving (dominant) approach compared with con-
ventional treatment. Other studies for patients with BMI
>35kg/m2 showed cost-effective results, with incremental
cost-effectiveness ratios (ICERs) below CHF 50,000 per
quality adjusted life-year (QALY) gained. Two studies as-
sessed cost-effectiveness for patients with BMI <35kg/m2,
and revealed ICERs below 50,000 per QALY gained for
bariatric surgery versus conventional treatment. Between-
study differences were related to approaches for the mod-
elling effectiveness and costs, time horizon, population,
type of intervention and possibly other unidentified rea-
sons. Gastric bypass appeared to be superior to gastric
banding, but was more expensive.
CONCLUSIONS: Nearly all studies found bariatric surgery
to be a cost saving or cost-effective compared with con-
ventional treatment. The adaptation of existing cost-effec-
tiveness analyses cannot be considered to give accurate
ICERs for Switzerland, but may have achieved an ap-
proximation of cost-effectiveness levels to be expected for
Switzerland. It has made the results of international cost-
effectiveness studies reported for different countries and
in different currencies more comparable, and may be use-
ful for individual countries in which financing or capacity
for economic analyses is scarce.
Keywords: bariatric surgery, body mass index, econom-
ics, cost effectiveness
Introduction
Obesity is a serious health problem associated with an in-
creased risk for comorbidities such as type 2 diabetes, hy-
pertension, obstructive sleep apnoea and musculoskeletal
disorders, and for increased mortality [1–3]. Latest glob-
al burden of disease estimates showed that the proportion
of adults with a body mass index (BMI) of ≥25 kg/m2
in 2013 was 36.9%, with a higher prevalence in women
than in men [2]. In addition, obesity with associated health
problems has a major economic impact on any healthcare
system [4, 5]. For example, in 2008 in the United States,
the medical care costs of obesity were $147 billion [5]. In
Switzerland, the estimated healthcare costs due to obesity
were estimated to be around CHF eight billion in 2011 [6].
Of the Swiss population, 30.8% are overweight (defined
as BMI 25.0–29.9 kg/m2) and 10.3% are obese (BMI ≥30
kg/m2) [6, 7]. Conventional treatment for obesity may in-
clude nutritional counselling by a nutritionist or physician,
behavioural therapy including psychotherapy, diets to re-
duce caloric intake, physical therapy including physiother-
apy and medication, either on their own or in combination
with other interventions.
If conventional treatment fails, bariatric (weight-loss)
surgery may be considered. Conservative treatment is con-
sidered to have failed if, during 2 years of treatment or
thereafter, a BMI of <35 kg/m2 cannot be reached and
maintained. Swiss statutory health insurance covers certain
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types of bariatric surgery for obese individuals with a BMI
≥35 kg/m2 independent of existing comorbidities [8].
There is a relatively broad international literature on the
cost effectiveness of bariatric surgery, but there are no sys-
tematic reviews that examine the transferability of inter-
national cost-effectiveness results for Switzerland or an-
other single country. The aims of this study were to (a)
identify and assess the quality reporting of published cost-
effectiveness studies of bariatric surgery, (b) assess their
transferability to Switzerland, and (c) adapt transferable
cost-effectiveness results to Switzerland. The underlying
notion was that gathering and synthesising international
evidence may achieve a certain approximation of cost-ef-
fectiveness levels to be expected for a single country, and
may be useful for individual countries in which financing
or the capacity for economic analyses are scarce.
Methodology
Literature search
A systematic literature search was made in the following
electronic databases: Medline, Embase, the Cochrane Li-
brary, and the Centre for Review and Dissemination (CRD)
databases including the Database of Abstracts of Reviews
of Effects (DARE), Cochrane reviews, and Health Tech-
nology Assessments (HTA) and the Economic Evaluation
Database from the UK National Health Service (NHS
EED). Search strings for additional databases were not de-
veloped because the above-listed selection of databases has
been reported to be both sufficient and very efficient [9].
The economic part of the search string was obtained from
the NHS research and development programme, which
performed a health technology assessment of “the clinical
effectiveness and cost-effectiveness of surgery for people
with morbid obesity: a systematic review and economic
evaluation” [10, 11]. The search strategy included key-
words and medical subject heading terms concerning cost,
cost-effectiveness and health economic studies. In the
Cochrane library we used the option to search for tech-
nology assessments and economic evaluations. Search re-
sults were restricted by selecting human studies only and
removing duplicates. The search was performed on 6 Au-
gust 2015. Details are provided in appendix 1.
Screening of search results
Screening of the literature comprised three phases. In the
first phase, all search results were screened by title. Titles
containing relevant keywords such as bariatric surgery,
costs, value, cost-effectiveness, cost-utility, quality of life,
and burden were considered as potentially relevant. In the
second phase, the abstracts of all papers with potentially
relevant titles were screened for relevant results – costs,
life years gained, quality adjusted life-years (QALYs) or
incremental cost-effectiveness ratios (ICERs). Two re-
viewers independently screened titles and abstracts for eli-
gibility. In the third phase, the full texts of articles with po-
tentially relevant abstracts were assessed for eligibility by
two reviewers independently. Any disagreements were re-
solved by consensus and discussion with a third reviewer
when needed.
Eligible full texts were defined as full-scale incremental
cost-effectiveness analyses, ideally, but not necessarily,
with an endpoint of cost per QALY gained or cost per
life-year gained, performed for Switzerland or a jurisdic-
tion with socioeconomic characteristics broadly similar to
Switzerland. Studies from north, central and western Eu-
ropean countries, the USA, Canada, Australia and New
Zealand were considered. Only publications available in
English, German, French or Italian were considered.
Extraction of information and quality of reporting
For each study included in the final review, the following
data were extracted by two reviewers independently:
1. Study population (including country, age and BMI
range of the patients)
2. Intervention
3. Comparator (including “conventional therapy” or
“current practice”)
4. Setting and perspective of the study
5. Cost types included and cost year
6. Type of model
7. Time horizon and discount rate (adjusting for differ-
ences in the timing of costs)
8. Approach to sensitivity analysis
9. Effectiveness
10. Costs ICER
This manuscript was prepared according to the PRISMA
flowchart reporting requirements (please refer to fig. 1)
[12].
The quality of reporting of the cost-effectiveness studies
was assessed using the Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) [13] 24-item
checklist, recommended by the International Society for
Pharmacoeconomics and Outcomes Research Health Eco-
nomic Evaluations Publication Guidelines Task Force. Se-
lected CHEERS criteria were defined as being necessary
in order to make a study not originating from Switzerland
qualitatively transferable and thus suitable for numerical
adaptation of ICER results to Switzerland. It was expected
that CHEERS items 4 (population), 7 (intervention/com-
parator) and 10 (outcome measures) would be met by all
studies assessed because studies failing any of these items
would not meet the eligibility criteria defined above [13,
14].
Assessment of transferability
A variety of groups worked on criteria for assessing qual-
itative transferability of studies between jurisdictions, us-
ing related multistep procedures [14–16]. For the present
study, none of the original models underlying the eligible
cost-effectiveness studies was available. Therefore we pur-
sued a modified approach described below and sum-
marised schematically in figure 2.
Essentially, the first step excluded studies that were not
full-scale health economic evaluation studies assessing in-
cremental cost-effectiveness, did not meet the PICO cri-
teria, or were performed for countries very different from
Switzerland in terms of socioeconomic characteristics. (PI-
CO stands for: P = patient, problem or population; I = in-
tervention; C = comparison, control or comparator; O =
outcome.) All remaining studies had to meet CHEERS cri-
teria 4, 7 and 10.
Secondly, studies not meeting CHEERS items 5, 6, 8, 13,
14 and 19 were regarded as not transferable owing to lack
of key information. In relation to item 19, the availability
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of costs and outcomes of interest for both the intervention
and the comparator strategies was considered fundamental.
Where articles only reported ICERs, the underlying study
was considered nontransferable (impossible to adapt the
direct healthcare costs) (fig. 2 and appendix 2) [14, 16].
The remaining studies were considered qualitatively trans-
ferable, and underwent numerical adaptation of cost-effec-
tiveness results.
The following transferability factors were considered:
1. Methodological characteristics (perspective of cost as-
sessment, discount rate, medical cost approach, pro-
ductivity cost approach)
2. Healthcare system characteristics (absolute and
relative prices in healthcare, clinical practice vari-
ation, differences in resource use, incentives and
regulations for health-care providers, technology
availability)
3. Population characteristics (demography, disease
incidence and prevalence, case-mix, life expectan-
cy, health-status preferences, acceptance, compli-
ance, incentives to the patients and productivity
and work-loss time)
For the majority of cost-effectiveness studies meeting the
general eligibility criteria we did not expect major trans-
ferability problems since methodological and population
characteristics were expected to be similar to Switzerland.
Figure 1: Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) diagram.Cost utility analysis, cost-effectiveness
analysis included: Medline, Embase, Cochrane, CRD (Centre for Reviews and Dissemination). CHEERS = Consolidated Health Economic
Evaluation Reporting Standards, ICER = incremental cost effectiveness ratio.
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Regarding healthcare system characteristics, we did not
expect big differences in availability of technology. Ab-
solute prices in healthcare were adapted numerically (see
section “Adaptation of cost-effectiveness”), whereas dif-
ferences in relative prices were expected to pose certain
issues. With respect to clinical practice, bariatric surgery
procedures should be well comparable across countries. In
contrast, standard care (the comparator strategy) was ex-
pected to vary across studies and countries. Therefore, we
assessed as far as possible what kind of clinical practice the
comparator groups were exposed to.
Adaptation of cost-effectiveness results to Switzerland
The cost data were adapted independently by two review-
ers and any disagreements were resolved by a third re-
viewer, based on an approach previously developed in a
study commissioned by the Swiss Federal Office of Public
Health, in order to estimate the costs of noncommunicable
diseases [17]. The cost data representing direct medical
costs to Switzerland were adapted in three steps: correction
for different levels of resource utilisation, for different
prices of healthcare services, and for change in the level
of resource utilisation and prices over time. Subsequently,
adapted ICERs were calculated. Although there is no of-
ficial threshold for cost per QALY gained in Switzerland,
a willingness-to-pay threshold of CHF 50,000 per QALY
gained were used, in line with published analysis for Swiss
setting [18]. The three steps are described below.
Resource utilisation
The types and quantities of healthcare resources used dif-
fered between countries. For the same disease, patients in
Switzerland often receive more medical treatment than in
other countries (i.e., they are treated more intensively for
an equivalent diagnosis). Therefore, a quantity correction
was based on the Organization for Economic Co-operation
and Development (OECD) statistics of healthcare expens-
es per capita, corrected for purchasing power. A correction
for differences in resource utilisation levels (unaffected by
price levels) was thus achieved [19]. Correction factors be-
tween Switzerland and the countries for which the select-
ed cost-effectiveness analyses were performed are shown
in appendix 3.
Prices of healthcare services
The price for the same set of healthcare services or treat-
ments is often different across countries. A price correction
was made by applying purchasing power parities provided
by the OECD as correction factors representing the propor-
tional costs for identical products in two countries [20]. For
more details, please see appendix 3.
Change in costs over time
For eligible cost-effectiveness studies performed in coun-
tries other than Switzerland, the two steps described above
achieved an approximate adaptation of reported costs. The
resulting estimates were valid for the same cost year as
in the original study. Corrections for change over time
up to 2012 (the latest available), our price year of refer-
ence, were based on the yearly growth rates of total Swiss
Figure 2: Steps for study selection and determination of transferability to another country. Studies falling in the lower left box were regarded
as being qualitatively transferable.CHEEERS = Consolidated Health Economic Evaluation Reporting Standards; PICO stands for: P = patient,
problem or population; I = intervention; C = comparison, control or comparator; O = outcome.
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healthcare expenditures [21]. This was expected to be ap-
propriate as, in addition to prices, the healthcare resources
used for different strategies of obesity treatment may have
changed over time. If the resource used could be assumed
to be constant over time, a simple adaptation using infla-
tion rates would be appropriate instead. The implications
of this alternative were assessed in a sensitivity analysis.
For more details, please see appendix 3.
Example of adaptation of an international CEA
A study by Craig et al. [22] reported that the total costs
for gastric bypass in the US in 2001 for a 35-year-old male
were US$ 68,000. To adapt the costs for Switzerland, the
mentioned costs were multiplied by the ratio Switzerland/
US for current expenditure on health, per capita, US$ pur-
chasing power parities, interpreted as the resource utilisa-
tion ratio between Switzerland and the US in 2001 (i.e.,
0.697) [23], by the purchasing power parity ratio in 2001
(i.e., 1.840) [24], and by the growth in healthcare ex-
penditures in Switzerland between 2001 and 2012 (i.e.,
1.492) [25]. This means that the estimated, adapted costs
for Switzerland in 2012 would be CHF 131,263 (68,600 ×
0.697 × 1.840 × 1.492).
Results
Systematic process of article selection
A total of 76 articles were included in the full-text review,
of which 55 were ineligible because of an inappropriate
comparator (comparator was not defined), noncomparative
design, unsuitable article type (reviews, commentary), or
inappropriate outcome measures (fig. 1). The remaining 21
articles fulfilled the inclusion criteria and were assessed
using the CHEERS checklist. However, only 15 articles
fulfilled criteria for qualitative transferability and were
thus suitable for numerical adaptation of ICER results to
Switzerland (table 1). There were no cost effectiveness
studies from Switzerland.
The six excluded studies (after assessment with CHEERS
checklist), Ananthapavan et al. [38], Anselmino et al. [39],
Faria et al. [40], Jensen et al. [41], McEwen et al. [42]
and Salem et al. [43], were found to be not qualitatively
transferable to Switzerland as they did not provide suffi-
cient information on costs (no clear information on cost
about intervention and comparator, year of the cost data
was missing, discounting information missing, or perspec-
tive of analysis was unclear) and effects (missing informa-
tion on how the quality adjustment life years or life years
gained was calculated).
Study and patient characteristics
Of the 15 included studies (table 1), six were from the
United States, four from the United Kingdom and one from
Australia. The remainder were from continental Europe.
All studies were published between 2002 and 2014 and all
but two (Craig et al., Borg et al.) [22, 27] reported fund-
ing sources. The perspectives of the studies were different.
Three studies adopted a healthcare perspective (Keating et
al., Mäklin et al., Wang et al.) [32-–36] and nine a pay-
er perspective (Picot et al. 2009, Clegg et al. 2003, Craig
et al., Picot et al. 2012, Pollock et al., Ikramuddin et al.,
Ackroyd et al., Campbell et al., Castilla et al.) [3, 10, 22,
26, 28, 29, 31, 34, 35]. Two were conducted from a soci-
etal perspective (Borg et al., Michaud et al.) [27, 33], and
in one study the perspective was not defined (i.e., payer,
health care or societal perspective) (Hoeger et al.) [30].
Six studies included type 2 diabetes mellitus patients with
BMI >35 kg/m2 [3, 26, 30–32, 34, 35]. Hoerger et al.
[30] additionally divided the study population into patients
with newly diagnosed diabetes and patients with estab-
lished diabetes. The rest of the studies incorporated pa-
tients with BMI >35 kg/m2 and, to a varying degree, obesi-
ty-related comorbidities such as type 2 diabetes, hyperten-
sion, coronary artery disease, stroke, and other life threat-
ening diseases. Most of the studies assessed patients with
BMI ranges above 35 kg/m2 (table 1). Only two studies
assessed lower BMI populations. Specifically, Borg et al.
[27] assessed costs and effects of bariatric surgery in a
population with BMI 30–34 kg/m2 and Keating et al. [32]
assessed the cost-effectiveness of laparoscopic adjustable
gastric banding (LAGB) in patients with BMI 30–40 kg/
m2.
The majority of studies assessed gastric bypass. Eight stud-
ies explicitly stated that gastric bypass was performed la-
paroscopically [3, 10, 26, 28, 29, 33, 34, 36]. In Craig et
al. [22] only open gastric bypass was included. Castilla et
al. [29] assumed 50% laparoscopic and 50% open gastric
bypass. In four studies on gastric bypass it was not clearly
stated if the intervention was performed laparoscopically
or openly [27, 30, 31, 44]. Nine studies reported the cost-
effectiveness of other operations such as adjustable gastric
banding (AGB) or LAGB [3, 26, 30–32, 34–36, 44], all
compared with conservative treatment or no surgery. Wang
et al. [36] reported on laparoscopic roux-en-Y gastric by-
pass (LRYGB), open roux-en-Y gastric bypass (ORYGB)
or LAGB, compared with conservative treatment.
Standard medical management, described as “conventional
therapy” or “current practice”, was typically a combination
of diet, exercise and behavioural modification, and was the
comparator in nine studies [3, 10, 26, 27, 29–32, 44]. Other
studies were very specific about current practice, reflecting
the population with type 2 diabetes, which included tight
glycaemic control, exercise and other behavioural modifi-
cations.
Most studies were cost-utility analyses, i.e., cost-effective-
ness analyses using QALYs as their benefit measure. The
only exception was the study by Michaud et al. [33], which
reported life years and costs per life year gained as out-
comes of interest. Decision analytic modelling employing
Markov elements or life tables was used in all studies.
Studies adopted various time horizons, ranging from life
time (Craig et al., Borg et al., Keating et al., Wang et al.,
Campbell et al., Castilla et al., Michaud et al., Hoerger et
al.,) [22, 27–30, 32, 33, 36] to 5 years (Ackroyd et al.)
[26] (table 1). Ten studies used 3.0% discounting for costs
and effects [22, 27–33, 36, 44]. One early study discounted
costs by 6.0% and effects by 1.5% [10], and the remaining
four studies used 3.5% discounting of costs and effects.
Measurement of cost and data sources
Types of costs included varied, depending on the chosen
perspective. The direct medical costs of interventions (gas-
tric bypass, LRYGB, AGB, LAGB) and comparator (con-
servative therapy, usual care) were reported in all cases.
All analyses aimed to include the costs of surgery and
related diseases. Only Michaud et al. [33] reported total
Systematic review Swiss Med Wkly. 2018;148:w14626
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lifetime medical costs (disease-specific and disease-non-
specific costs). Only two studies included a societal per-
spective and reported indirect costs [27, 33]. The accuracy
in reporting types of costs and the sources of cost data used
varied. Details are provided in appendices 4 and 5.
Measurement of clinical effects and data sources
Modelling of clinical effects included body weight loss
or BMI reduction, reduced or delayed comorbidities (e.g.,
type 2 diabetes remission), complications and mortality re-
duction. Specifics varied across studies and were partial-
ly influenced by the study population and time horizon.
Almost all studies included short-term effects related to
bariatric surgery, except one study [31]. Long-term effects
were measured in terms of reduced BMI and reduced mor-
tality [22, 27–29, 32, 33]. Studies also considered surgery-
related complications or adverse events in their analyses.
However, it was not always clear how surgery-related com-
plications were defined. The most frequent complications
listed were reoperation [3, 10, 22, 26, 28, 30–34, 44], in-
fection [3, 10, 22, 26, 32, 34], pulmonary embolism [3, 22,
26] and abdominoplasty [3, 22, 30, 44]. All but three stud-
ies included surgical mortality (mortality during 30 days
after surgery), except for three studies [26, 33, 34]. Addi-
tional information about clinical effects included in the in-
dividual studies can be found in appendices 6, 7 and 8.
The sources of effectiveness estimates varied across stud-
ies. Some sources were used more frequently than others.
For example, the results of the Swedish Obese Subjects
(SOS) study [37, 45–47] was used by eleven studies as
their main source for effectiveness estimates (appendix 8).
Almost all studies combined survival estimates with utili-
ties to generate QALYs as their main summary measures
of effectiveness, and one study considered duration of sur-
vival only [33].
Adaptation of economic evaluation results to Switzer-
land
Differences in costs and effects as originally reported by
the 15 transferable studies are summarised in appendices 9
and 10. Based on the criteria set by the authors, the results
indicate that bariatric surgery is cost-saving or cost-effec-
tive.
Adapted results of the 15 transferable studies were quite
consistent. Differences in costs and effects between
surgery and conventional treatment (usual care) are pre-
sented in figure 3 and appendices 11 and 12.
The vast majority of adapted studies of patients with BMI
values >35 kg/m2 indicated bariatric surgery compared
with conventional treatment or nonsurgical management to
be a cost saving (dominant [cost saving and increase in
QALYs and life years] or potentially cost-effective (ICERs
were generally below CHF 50,000 per QALY gained).
More specifically, four studies with long time horizons (10
years to lifetime) showed cost saving results (fig. 3, ap-
pendices 11 and 12) [27, 29, 32, 44]. Other studies [3, 10,
22, 28, 30, 31, 34–36] showed cost-effective results, even
the study by Ackroyd et al. [26], which utilised a short
time horizon (5 years). In the study by Michaud et al. [33],
where the effectiveness outcome of interest was life-years
gained rather than QALYs gained, the adapted cost-effec-
tiveness ratio was below CHF 9000 per life-year gained.
From a societal perspective, adapted ICERs based on Borg
et al. were below CHF 3000 per QALY gained for females
aged 45–54 years with BMI 40–44 kg/m2, when gastric by-
pass was compared with conservative treatment. For males
aged 45–54 years with BMI 40–44 kg/m2, gastric bypass
was cost-saving and thus dominant [27]. Michaud et al.
[33] also reported cost-effectiveness from a societal per-
spective, for US patients with BMI >40 kg/m2, or with
BMI >35 kg/m2 and a high risk of comorbidities. Here, the
adapted ICER for gastric bypass compared with conserva-
tive treatment was CHF 8158 per life-year gained [33].
For patients in the BMI category <35 kg/m2, the cost-effec-
tiveness of bariatric surgery compared with conventional
treatment (usual care) treatment was assessed only by Borg
et al. [27] and Picot et al. [34], and both applied a lifetime
horizon. In the study by Borg et al. [27], the adapted ICER
was below CHF 3000 per QALY gained. In the study by
Picot et al. (2012) [34], the adapted ICER was below CHF
50,000 per QALY gained.
From the societal perspective, for patients in the BMI class
<35 kg/m2, the cost-effectiveness of bariatric surgery com-
pared with conservative treatment was assessed only by
Borg et al. [27], who reported an adapted ICER of CHF
10,458 per QALY gained for females and CHF 12,365 per
QALY gained for males.
Procedure-specific differences in terms of benefits and ef-
ficiency appear to exist. When LRYGB and LAGB were
compared with conservative treatment, LRYGB appeared
to be better than gastric banding in terms of clinical ben-
efits (QALYs gained and life-years saved), but also more
expensive [26, 30, 36, 44].
Difference between cost-effectiveness studies
In order to understand the observed cost-effectiveness dif-
ferences between studies, we assessed potential explana-
tory factors, which are described in appendix 14. Briefly,
QALY estimates were a major driver in the difference be-
tween cost-effectiveness studies. Also, a partial explana-
tion for the differences between cost-effectiveness studies
may be in the cost items taken into consideration, and dif-
ferences in the modelling techniques of bariatric surgery.
Sensitivity analysis
The aim of the sensitivity analysis was to assess the impact
on ICERs adapted for Switzerland when the adjustment
of costs over time was based on inflation rates instead of
the increase in healthcare costs. This alternative approach
to calculating adapted costs and ICERs had no large ef-
fect. There were no substantial differences for the stud-
ies by Borg et al. [27] and Castilla et al. [29], which
were quite recent (cost year 2012). The largest impact on
ICERs was seen for the older studies by Clegg et al. (2003)
[10] (difference −31.70%) and Craig et al. [22] (differ-
ence −28.07%) (appendix 13). For the other 11 studies, the
change remained below 20%.
Discussion
The cost-effectiveness of bariatric surgery was system-
atically reviewed, using data from 15 cost-effectiveness
analyses performed in a number of European countries, the
US and Australia. The majority of studies assessed cost-ef-
fectiveness as cost per QALY gained, with time horizons
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that ranged from 5 years to lifetime. Results varied mainly
owing to: inclusion criteria with regards to age, BMI class,
severity of obesity and comorbidities; the assessment and
modelling of costs and effects; and the perspective of cost
assessment taken.
Nearly all studies assessing patients with BMI >35 kg/m2
indicated bariatric surgery to be cost-saving or cost-effec-
tive based on the criteria set by the authors. This result of
the present systematic review is consistent with an earlier
systematic review published by Padwal et al. in 2011 [50].
The latter suggested that, based on 13 economic evalua-
tions, bariatric surgery compared with conservative treat-
ment appeared attractive, with ICERs ranging from $1000
to $40,000 per QALY gained [50]. However, the authors
did not make any definitive conclusions about the cost-ef-
fectiveness of alternative surgical procedures.
Similarly, adapted ICER results for patients with a BMI
>35 kg/m2 indicated a cost saving (dominant) situation or
showed ICERs of CHF 8000 to CHF 44,000 per QALY
gained. For patients in the BMI <35 kg/m2 category, the
adapted cost-effectiveness of bariatric surgery compared
with conventional treatment was below CHF 3000 per
QALY gained, from a healthcare perspective (Borg et al.
2014 [27]) or below CHF 50,000 per QALY gained in the
study by Pico et al. [34]. Procedure-specific differences in
benefits and efficiency appear to exist. However, to date,
there is no direct economic evaluation comparing LRYGB
with LAGB. Therefore, further information is required to
understand the long-term comparative effectiveness and
cost-effectiveness of different bariatric procedures.
The adaptation of cost-effectiveness results may have al-
lowed a comparison of results across studies, and an ap-
proximation of cost-effectiveness levels to be expected for
Switzerland. The majority of studies were from a payer
perspective [3, 10, 22, 26, 28, 29, 31, 34, 50] and two were
from a societal perspective [27, 33]. It should be noted
that adapted ICERs from a payer perspective may reflect
a Swiss statutory health insurance perspective (taking into
account the direct medical costs of all healthcare services
covered by the Swiss statutory health insurance, irrespec-
Figure 3: Cost-effectiveness plan, based on costs adapted to Switzerland and original effect estimates.Blue dots represent the cost-effective-
ness studies assessing laparoscopic gastric bypass (or other term used in the studies gastric bypass (GB), laparoscopic roux-en-Y gastric by-
pass (LRYGB), roux-en-Y gastric bypass (RYGB), versus conservative treatment. Red dots represent cost-effectiveness studies assessing
other bariatric surgeries (adjustable gastric banding (AGBAN), gastric banding (GBAN), laparoscopic adjustable gastric banding (LAGBAN)
conservative (open) roux-en-Y gastric bypass (ORYGB) versus conservative treatment. In the case of studies providing results for different pa-
tient groups, results were selected for presentation based on the longest available time horizon (if there was more than one time horizon avail-
able), female gender (when available in the study) and BMI >35 kg/m2. Ackroyd et al. [26] described results based on three different countries,
Campbell et al. [28] for two estimates of treatment effects (by Angrisani [48] and O'Brien [49]), Hoerget et al. [30] for two diabetes groups,
Wang et al. [36] for two types bypass surgeries and gastric banding, and Picot et al. for two different banding techniques. From the Borg et al.
study [27], we selected the results for female patients aged 45–54 years, with BMI 40 kg/m2.
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tive of actual payer), rather than an immediate insurer per-
spective. This is because insurers cover only about 45%
of inpatient costs for acute care. The rest is borne by the
Swiss cantons.
Limitations of the systematic review
This systematic review had a number of limitations. First,
the screening of abstracts was restricted to English, Ger-
man, French, and Italian language publications, which may
have led to excluding evidence published in other lan-
guages. Second, the assessment of qualitative transferabil-
ity to Switzerland was based on a combination and adap-
tation of published criteria. The estimates emerging from
subsequent numerical adaptation of cost results cannot be
directly interpreted as “ICERs for Switzerland”, only as an
approximation of cost-effectiveness levels to be expected
for Switzerland.
Limitations of reviewed cost effectiveness studies
The reviewed cost-effectiveness studies utilised changes in
BMI rather than changes in body weight as a percentage
change from baseline, and this was due to lack of under-
lying clinical evidence. Additionally, some studies, again
owing to lack of evidence, assumed a re-increase of BMI
after a certain time and then a stable difference after the
observation period. However, descriptions were not always
entirely clear. If the difference in BMI was maintained for
longer, this tended to translate into higher net differences
in terms of life-years lived and QALYs gained for surgery.
Some studies strongly focused their cost-effectiveness
models on the effects on type 2 diabetes. Three of these
studies (Ikramuddin et al., Keating et al., Pollock et al.)
[31, 32, 35] found relatively small QALY differences; an
exception was Hoerger et al. [30]. This might be because
the focus on diabetes in these studies led to potentially in-
complete coverage of other effects, and thus underestima-
tion of QALY differences.
In addition, it should be noted that in the identified cost-
effectiveness studies, the modelling of effectiveness was
based on short-term clinical trials and longer-term obser-
vational data, such as the Swedish SOS study [47]. This is
a frequently seen in health economic evaluations with long
time horizons, where an extrapolation of effects observed
in clinical trials is needed. Data from observational studies
are crucial to understanding the long-term impact of inter-
ventions in clinical practice, but are generally affected by
higher risks of bias than randomised studies.
Another limitation of the included cost-effectiveness stud-
ies was that there were no long-term quality of life data
they could have built upon. Bariatric surgery has been
shown to improve quality of life in the short-term, and
there were cross-sectional data on the correlation between
BMI and quality of life. As such, this information was
modelled in the available economic evaluations. The au-
thors undertook a number of sensitivity analyses to demon-
strate the robustness of the data presented, but not all fol-
lowed the rule of varying all parameters with potentially
relevant, inherent uncertainty.
A final limitation concerns the outcomes considered. It has
been well known for many years that diseases such as di-
abetes, myocardial infarction or stroke are associated with
obesity. Not surprisingly, the costs of these diseases are of-
ten included in cost assessments of bariatric surgery. How-
ever, bariatric surgery may also have a positive or negative
impact on the occurrence of additional, potentially costly
diseases. For example, the effects of bariatric surgery on
bone mineral density have recently been discussed as po-
tentially relevant [51, 52]. Bone mineral loss after bariatric
surgery could potentially increase the risk of fractures.
This would lead to higher costs and reduced cost-effective-
ness.
Conclusions
Nearly all studies found bariatric surgery to be a cost sav-
ing or cost-effective, compared with conventional treat-
ment. Differences were due to approaches in the modelling
of effectiveness, costs, time horizon, population studied,
exact type of intervention studied, and possibly other
unidentified reasons. The adaptation process of existing
cost-effectiveness-analysis cannot be interpreted as achiev-
ing certain ICERs for Switzerland, but may have achieved
an approximation of cost-effectiveness levels to be expect-
ed for Switzerland. It has certainly made the results of in-
ternational cost-effectiveness studies, reported for differ-
ent countries and in different currencies, more comparable,
and may be useful for individual countries in which financ-
ing or capacity for economic analyses is scarce.
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Table 1: Characteristics of the cost-effectiveness studies included.
Study Population/country Age at time of
intervention
Intervention Comparator Perspective/setting
year
Time
frame
Discounting Modelling
Ackroyd
2006 [26]
Patients with a BMI of >35
kg/m2 and type 2 diabetes
in Germany, UK and France
Not reported Laparoscopic gas-
tric bypass and ad-
justable gastric
banding
Conservative
treatment
Payers perspective
2005
5 years 3.5% Decision analytic
modelling
Borg 2014
[27]
Females and males in Swe-
den with age below and
above 55 years of age.
Stratum age 45–54 years
and BMI 40–44 kg/m2 as
base case
Stratum age
45–54 years in
the base case
Gastric bypass (not
specified if laparo-
scopic or open)
Conservative
treatment
Societal perspective
2012
Life 3% A Markov micro-
simulation model
Campbell
2010 [28]
Patients with BMI >40 kg/
m2 or BMI >35 kg/m2 with
comorbid conditions in the
US
18–74 years Laparoscopic roux-
en-Y gastric bypass
and laparoscopic
adjustable gastric
banding
No intervention Third-party payer
2006
Life 3% Markov model
Castilla
2014 [29]
79 patients from Spain with
an average BMI of 50.7 kg/
m2 (range 36.6 to 76.3 kg/
m2)
18–55 years Gastric bypass
(50% laparoscopic
and 50% open)
Usual care Payer perspective
2012
5, 10, 15,
20 years
and life
3% Discrete-event sim-
ulation model
Clegg 2003
[10]
Hypothetical cohort of 100
patients, 90% females from
the UK with an average BMI
of 45 kg/m2
40 years Laparoscopic gas-
tric bypass and la-
paroscopic ad-
justable gastric
banding
Nonsurgical
management
NHS / personal social
services perspective
1999–2000
20 years Costs 6%
and QALY
1.5%
Results are based
on a systematic re-
view
Craig 2002
[22]
Severely obese >40 kg/m2
patients from the US who
were non-smokers without
cardiovascular disease
35–55 years Open gastric by-
pass
No surgery Payer perspective
2001
Life 3% Decision model
Hoerger
2010 [30]
Patients from the US with
BMI >35 kg/m2 and new or
established diabetes
Not reported Gastric bypass and
banding surgery
(not specified if la-
paroscopic or open)
Usual diabetes
care
Unclear
2005
Life 3% Markov model
Ikramuddin
2009 [31]
Diabetes patients from the
US, 22.1% were males with
a mean BMI of 48.4 kg/m2
Mean 50.1 years Laparoscopic roux-
en-Y gastric bypass
Standard med-
ical treatment
Third-party payer per-
spective/2007
35 years 3% Markov model
Keating
2009 [32]
Patients with recently diag-
nosed type 2 diabetes from
Australian with a BMI of
30–39.9 kg/m2, 55% female
Mean 49 years Laparoscopic ad-
justable gastric
banding
Conservative
therapy
Healthcare perspective
2006
Life 3% Markov model
Mäklin 2011
[25]
Patients from Finland with a
mean BMI of 47 kg/m2
(38-59 kg/m2), 35% male
Mean 43 years Gastric bypass and
gastric banding (not
specified if laparo-
scopic or open)
Ordinary treat-
ment
Health care perspective
2010
10 years 3% Combination of de-
cision tree and
Markov model
Michaud
2012 [33]
Current eligibility: BMI >40
kg/m2 or BMI >35 kg/m2
with high risk comorbidities
(extended eligibility to those
with BMI >35 kg/m2 or BMI
>30 kg/m2 with qualifying
comorbidities)
50 years Laparoscopic roux-
en-Y gastric bypass
Baseline man-
agement
Societal perspective
2010
Life 3% Future Elderly Mod-
el, microsimulation
model of aging and
health
Picot 2009
[3]
Patients with a BMI of >40
kg/m2 from the UK
40 years Laparoscopic gas-
tric bypass and ad-
justable gastric
banding
Nonsurgical
comparator
NHS and personal so-
cial services
2007–2008
20 years 3.5% Transition model
Picot 2012
[34]
Patients with class I and II
obesity (BMI 30–40 kg/m2)
with type 2 diabetes or
class I obesity (BMI 30–35
kg/m2) in the UK
Unclear, presum-
ably between
41.8 and 46.6
years
Laparoscopic ad-
justable gastric
banding
Nonsurgical in-
terventions
UK NHS
2009–2010
2, 5, and
20 years
3.5% Transition model
Pollock
2013 [35]
Obese patients from the UK
with type 2 diabetes, 46.5%
were males with a mean
BMI of 42.4 kg/m2 (SD 4.5),
Duration of diabetes 1 year
(SD 0.33)
46.9 years Laparoscopic ad-
justable gastric
banding
Standard med-
ical manage-
ment
National Health Service
2010
40 years 3.5% Computer model of
diabetes
Wang 2014
[36]
The reference was defined
as US female with BMI of
44 kg/m2 (simulation range
18–70 years)
53 years Laparoscopic gas-
tric bypass, conser-
vative (open) roux-
en-Y gastric bypass,
and laparoscopic
adjustable gastric
banding
Nonsurgical in-
tervention
Health care perspective
2010
Life 3% Two-part model us-
ing a deterministic
approach for the
first 5-years post-
surgery and sepa-
rate empirical fore-
casts for the natural
history of BMI
BMI = body mass index; NHS = National Health Service; QALY = quality adjusted life-year; SD = standard deviation Comparator information. Ackroyd 2006 [26]: monitoring or
medically guided dieting; Germany – 6 general practice consultations, 2 lab. assessments, 365 food substitutes; France – 30 days in institution, 6 specialist consultations, 2
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lab. assessments, 2 food substitutes; UK – 4 general practice consultations, 4 nurse consultations, 2 dietician consultations, 1 lab. assessment, 56 food substitutes. Borg 2014
[27]: conservative treatment alternative consisted of the prevalent mixture of nonsurgical obesity treatments (Sjöstrom 2013 [37]). Castilla 2014 [29]: usual care – diet, exercise,
behaviour modification. Clegg 2003 [10]: nonsurgical management, 4 general practice visits, 2 dietitian contacts, 2 practice nurse contacts, 2 district nurse contacts, every 3 years
a very low calorie diet for 12 weeks. Hoerger 2010 [30]: usual diabetes care including tight glycaemic control. Ikramuddin 2009 [31]: standard medical treatment of obese type
2 diabetes patients. Keating 2009 [32]: conservative therapy (diet, physical activity and medical therapy). Mäklin 2011 [36]: ordinary treatment, considered to include a range of
interventions from brief advice given by physicians to intensive conservative treatment, as there is no standard medical treatment for obesity in use in Finland. Picot 2009 [3]:
nonsurgical comparator, primarily monitoring rather than active treatment. Types of costs are reported in appendices 3 and 4.
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Appendices The appendices 1 to 14 are available in separate file for
downloading at https://smw.ch/en/article/doi/
smw.2018.14626/
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